Smruti Mohanty, MD
Gastroenterology · Brooklyn, NYNPI 1922160472
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,745 of the $128,765 with a category attached, or 90.7%. 11 manufacturers reported payments, led by AbbVie at 35.5% of the total. Reporting peaked in 2019 at $51,134 and has fallen 50.3% since, to $25,410 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $847.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Madrigal Pharmaceuticals$31K
- Gilead$30K
- Intercept Pharmaceuticals, Inc.$17K
- Eisai Inc.$4K
- Shire North American Group Inc$125
- plus $435 from 5 others
Across 13 payments — averaging $2044.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dova Pharmaceuticals$12K
- Bausch Health US, LLC$12K
- AbbVie$3K
What the payments were for
- Consulting fees$1,2081%
- Speaking & faculty fees$116,74591%
- Travel & lodging$4,6764%
- Food & beverage$6,1225%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $45,753 |
| Madrigal Pharmaceuticals | 34 | $31,394 |
| Gilead | 47 | $29,861 |
| Intercept Pharmaceuticals, Inc. | 15 | $17,230 |
| Eisai Inc. | 3 | $3,968 |
| Shire North American Group Inc | 2 | $125 |
| Dexcom, Inc. | 1 | $124 |
| AstraZeneca | 1 | $123 |
| Boehringer Ingelheim | 1 | $107 |
| Exact Sciences | 2 | $65 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$42,286
- REZDIFFRA$29,452
- Epclusa$25,762
- OCALIVA$17,230
- LENVIMA$3,968
- Rinvoq$161
- RESMETIROM$147
- DEXCOM G7 GSS (161)$124
- DEXCOM STELO GLUCOSE BIOSENSOR$124
How this compares
$128,765 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 43 | $716 |
| Famotidine | 33 | $522 |
| Omeprazole | 17 | $272 |
| Pantoprazole Sodium | 45 | $241 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $226 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Brooklyn
- Sam MoskowitzBrooklyn$332K
- Jianjun LiBrooklyn$211K
- Nison BadalovBrooklyn$200K
- Kevin TinBrooklyn$168K
- Jonathan ErberBrooklyn$164K
- Rabin RahmaniBrooklyn$155K
- Kayane Hanna-HindyBrooklyn$151K
- Kadirawelpillai IswaraBrooklyn$148K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.